Singapore markets closed

Exicure, Inc. (XCUR)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
0.3300-0.1127 (-25.46%)
At close: 04:00PM EDT
0.3400 +0.01 (+3.03%)
After hours: 07:42PM EDT

Exicure, Inc.

2430 North Halsted Street
Chicago, IL 60614
United States
847 673 1700

Full-time employees13

Key executives

NameTitlePayExercisedYear born
Mr. Paul KangCEO & DirectorN/AN/A1962
Ms. Jiyoung HwangCFO & DirectorN/AN/A1976
Mr. Joshua MillerChief Accounting OfficerN/AN/A1976
Mr. Bart AndersonSenior Director of R&DN/AN/AN/A
Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Exicure, Inc., an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.

Corporate governance

Exicure, Inc.’s ISS governance QualityScore as of 1 May 2024 is 10. The pillar scores are Audit: 10; Board: 10; Shareholder rights: 7; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.